Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study
about
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an examplePredictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis PatientsTNF inhibitor therapy for rheumatoid arthritis[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data].Reduction in sickness absence in patients with rheumatoid arthritis receiving adalimumab: data from a German noninterventional study.Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.NF-κB and Rheumatoid Arthritis: Will Understanding Genetic Risk Lead to a Therapeutic Reward?anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis.Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus
P2860
Q26766368-FC505344-B5C9-4ABE-83A5-AA9DCC6884BFQ27692641-2E45AF32-9C6A-415A-BDE8-76F472579C05Q28551075-D869DAB1-6FF5-4405-8C7E-59C18DC25FABQ28972424-543365CC-9E9C-4CAC-9CF5-A37686BDF654Q30699616-2734CBBD-7360-462C-9BEF-F25CEB5EED73Q34114195-FB2ED7A9-60B0-47A5-8F6F-D7198C8EBE69Q35577993-8CFF295E-19F2-4B45-AFBA-FAC1C304E562Q37691090-E7904294-CE7E-4BEE-A404-6B3F0739E394Q38200094-7C92F274-1D45-4650-AFB5-A116454FCBDCQ38207759-62F0447F-F12D-45B3-BAAA-AD15A80AC277Q40875239-89B8A4DB-89CF-442A-A22C-2485B4226BECQ42053368-ADADE357-C106-466B-A7AC-35CFCCFE4C53Q57115262-6FC43B16-9C72-4B47-AD5C-46CC6608DF29
P2860
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of patient and disease ...... rventional observational study
@ast
Impact of patient and disease ...... rventional observational study
@en
type
label
Impact of patient and disease ...... rventional observational study
@ast
Impact of patient and disease ...... rventional observational study
@en
prefLabel
Impact of patient and disease ...... rventional observational study
@ast
Impact of patient and disease ...... rventional observational study
@en
P2093
P2860
P50
P1476
Impact of patient and disease ...... rventional observational study
@en
P2093
Andreas Krause
Bianca M Wittig
Constanze Richter
Ekkehard Röther
Holger Gnann
Siegfried Wassenberg
Wolfgang Spieler
P2860
P2888
P304
P356
10.1007/S00296-011-2033-5
P577
2011-08-06T00:00:00Z
P5875
P6179
1042573311